Motixafortide (Aphexda)

Motixafortide is a cyclic peptide that blocks the CXCR4 receptor to solve a real, unglamorous problem in cancer care: some multiple myeloma patients can't be coaxed into shedding enough blood stem cells for their own transplant using the standard drug (G-CSF) alone. A large placebo-controlled Phase 3 trial found it worked dramatically better than placebo at getting patients collected in one or two apheresis sessions instead of several, and the FDA approved it in 2023 on that evidence.

The problem it solves

Before an autologous stem cell transplant — used most often in multiple myeloma — a patient's own blood-forming stem cells have to be collected from the bloodstream by apheresis, then reinfused after high-dose chemotherapy. Those stem cells normally sit anchored in bone marrow, held there partly by a chemical tether: the CXCR4 receptor on the stem cell binds CXCL12 (also called SDF-1), a signal made by marrow cells, that keeps it in place. The standard mobilization drug, filgrastim (G-CSF), coaxes stem cells into circulation well enough for most patients, but a meaningful minority don't mobilize enough cells to hit the collection target in a reasonable number of apheresis sessions — a real, practical bottleneck in transplant scheduling. Motixafortide (Aphexda, BioLineRx) is a cyclic peptide that directly blocks CXCR4, releasing the tether and letting more stem cells enter the bloodstream where they can be collected. It isn't the first drug built on that mechanism — plerixafor (Mozobil), a smaller CXCR4-antagonist molecule, was approved for the same purpose in 2008 — but motixafortide binds CXCR4 with slower dissociation kinetics, which is the basis for its single-dose, once-per-apheresis-day regimen.

The GENESIS trial

Motixafortide's approval rests on the Phase 3 GENESIS trial (Crees ZD, Rettig MP, Jayasinghe RG, et al., "Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial," Nat Med 2023;29(4):869-879, PMID 37069359, DOI 10.1038/s41591-023-02273-z), a double-blind, placebo-controlled study that randomized 122 adults with multiple myeloma undergoing transplant, 2:1, to motixafortide plus G-CSF or placebo plus G-CSF, across 18 sites in five countries. The primary endpoint — collecting at least 6×10⁶ CD34+ cells per kilogram within two apheresis days — was met by 92.5% of the motixafortide group versus 26.2% of the placebo group (odds ratio 53.3, 95% CI 14.12-201.33, p<0.0001). On the stricter secondary endpoint, hitting that same target in a single apheresis day, 88.8% of the motixafortide group succeeded versus 9.5% of the placebo group (odds ratio 118.0, 95% CI 25.36-549.35, p<0.0001) — a difference large enough that most motixafortide patients avoided a second collection day entirely.

FDA approval and how it's used

The FDA approved Aphexda on 8 September 2023 (a Friday; BioLineRx's public announcement followed the next business day, 11 September), in combination with filgrastim, to mobilize hematopoietic stem cells for collection and subsequent autologous transplant in patients with multiple myeloma — the trial population GENESIS enrolled. It's dosed at 1.25 mg/kg by subcutaneous injection, given 10 to 14 hours before the start of apheresis (typically after several days of G-CSF priming, the standard mobilization regimen), with a second dose permitted before a third apheresis day if needed. The most common adverse reactions in the trial were transient, mild-to-moderate injection-site reactions — pain in about half of patients, redness in roughly a quarter — along with a labeled warning (not a boxed warning) about the risk of hypersensitivity and anaphylactic reactions during or shortly after injection.

Beyond multiple myeloma

Motixafortide carries FDA (February 2019) and EMA (January 2020) orphan drug designations for pancreatic cancer, where it's being tested in earlier-phase trials in combination with checkpoint inhibitors and chemotherapy — not an approved use, and evidence there is still investigational. Separately, the same CXCR4-blocking mechanism is being tested in early-phase trials as a way to mobilize CD34+ stem cells ahead of gene therapy in sickle cell disease (ClinicalTrials.gov NCT05618301, NCT06442761) — a genuinely different rationale from the myeloma indication, since G-CSF itself can trigger dangerous vaso-occlusive crises in sickle cell patients and isn't a safe mobilization option for that population. Neither the pancreatic cancer nor the sickle cell disease use is an approved indication anywhere as of this review.

Current status

BioLineRx markets Aphexda in the US for its approved multiple myeloma mobilization indication, administered in a hospital or transplant-center setting alongside a treating hematologist-oncologist's standard mobilization protocol. As a specialty, injectable, hospital-administered supportive-care drug tied to a specific transplant procedure, there is no wellness, bodybuilding or grey-market interest in motixafortide that we could find.